Previous 10 | Next 10 |
2023-12-28 16:12:39 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earnings data for PMV Pharmaceuticals Financial information ...
2023-11-14 18:50:05 ET Summary PMV Pharmaceuticals' phase 1/2 trial of its drug, PC14586, in solid tumors with a Y220C p53 mutation produced initial data in 2022, but the response was mixed. A 2023 update on data from the phase 1/2 trial is a net positive, in my opinion, with conf...
PMV Pharmaceuticals Inc. (PMVP) is expected to report $-0.45 for Q3 2023
2023-11-09 13:22:55 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: A 5-Month Run-Up Is Justified Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earnings data for PMV Pharmaceuticals Financial information for PMV Pharmaceuticals ...
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven months An overall response rate ...
2023-10-12 13:26:41 ET More on Femasys, Jaguar Health, etc. Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript LogicMark, Inc. (LGMK) Q2 2023 Earnings Call Transcript Femasys regains Nasdaq compliance Jaguar Health's Napo Pharma gets patent in Japan ...
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in multiple tumor types including ovarian, breast, prostate, lung, and endometrial cancer with m...
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ong...
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutation Company to host KOL webinar on October 12, 2023 to review data and p...
2023-08-30 09:20:30 ET Summary PMV Pharmaceuticals is closing in on updated results from a phase 1/2 study of PC14586, a p53 reactivator with potential in various cancer types. The company plans to start phase 2 work in early 2024, having already engaged in end of phase 1 talks wi...
News, Short Squeeze, Breakout and More Instantly...
PMV Pharmaceuticals Inc. Company Name:
PMVP Stock Symbol:
NASDAQ Market:
PMV Pharmaceuticals Inc. Website:
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Off...
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOn...
2024-05-13 08:30:02 ET Craig-Hallum analyst issues BUY recommendation for PMVP on May 13, 2024 07:30AM ET. PMVP was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recommendations...